An Updated Evidence Assessment of the Genetic Causes of Dilated Cardiomyopathy

The ClinGen Dilated Cardiomyopathy Gene Curation Expert Panel's 2024-2025 reassessment significantly expanded the known genetic architecture of DCM by classifying 35 gene-disease relationships as high evidence, including 11 newly identified autosomal recessive genes, thereby providing an updated, evidence-based framework to guide clinical genetic testing and care.

The Gist

Imagine the human heart as a complex, high-performance engine. Sometimes, this engine develops a condition called Dilated Cardiomyopathy (DCM). Think of this like the engine's main chamber stretching out and becoming weak, making it hard to pump blood efficiently. This isn't just a mechanical failure; often, the blueprint for the engine—the DNA—has a typo or a missing instruction.

For years, doctors and scientists have been trying to find exactly which "typos" in the DNA cause this heart failure. They have a team of expert detectives called the ClinGen Gene Curation Expert Panel. Their job is to sift through thousands of research papers to figure out: "Is this specific gene actually the culprit, or is it just a suspect that looks guilty but isn't?"

The Big Update: A Five-Year Detective Story

This paper is the team's 2025 update on their investigation. Five years ago (in 2020), they had only confirmed 19 genes as the definite "bad actors" causing DCM.

In the time since, the world of genetic research exploded. It's like the detectives suddenly had access to a massive new library of case files. They went back to their old cases to re-check them and opened hundreds of new files to see if there were new suspects.

Here is what they found:

• The List Grew: They didn't just find a few new suspects; they expanded the list of confirmed "bad actors" from 19 to 35.
• The "Recessive" Surprise: The biggest shock was discovering that many of these new genes work differently than the old ones.
  • The Old Way (Dominant): Imagine a gene is like a light switch. If you have one broken switch (from one parent), the light goes out. This is Autosomal Dominant (AD).
  • The New Way (Recessive): Now, imagine you need two broken switches (one from mom, one from dad) for the light to go out. If you only have one broken switch, the other one keeps the light on. This is Autosomal Recessive (AR).
  • The Metaphor: The team found that a huge chunk of these new genes (about 69% of the new high-evidence ones) only cause heart trouble if the child inherits two broken copies. This is especially common in children with heart issues, often in families where the parents are related (consanguineous), which increases the chance of passing down two identical broken copies.

How They Decided Who is Guilty

The team didn't just guess. They used a strict scoring system, like a video game where you earn points for evidence.

• Genetic Evidence: Did the gene show up in sick people? Did it skip healthy people? (Points for family trees).
• Experimental Evidence: Did scientists test the gene in a lab (like in a petri dish or a mouse) and see it break the heart? (Points for lab tests).

The Verdicts:

• Definitive/Strong/Moderate (The "Guilty" List): 35 genes earned enough points to be put on the official "Do Not Trust" list. If a patient has a broken copy of one of these, doctors can say, "Yes, this is likely the cause."
• Limited (The "Suspects"): 29 genes are still on the fence. They have some suspicious activity, but not enough proof to be convicted yet. They might be guilty, or they might just be innocent bystanders.
• No Known Relationship (The "Innocent"): 4 genes were cleared. They have nothing to do with this specific heart problem.
• Disputed (The "He Said, She Said"): 4 genes are still being argued over by scientists.

Why This Matters for Real People

Think of this update as updating the map for doctors navigating a patient's genetic test results.

1. Better Diagnosis: Five years ago, if a child had heart failure, doctors might have tested 19 genes. If none matched, they were stuck with an "Unknown Cause." Now, they can test 35 genes. This means more families get answers.
2. Family Planning: Knowing if a gene is "Dominant" or "Recessive" changes the advice for families.
   • If it's Dominant, there's a 50% chance a parent passes it to a child.
   • If it's Recessive, the parents might be healthy "carriers" (they have one broken switch but are fine), but they have a 25% chance of having a child with two broken switches.
3. Avoiding False Alarms: The team also realized that some genes (like MYBPC3) were previously thought to be major causes of DCM, but the evidence was shaky. They downgraded them. This is crucial because it stops doctors from panicking over a genetic result that might not actually be the problem.

The Bottom Line

The genetic landscape of heart failure is huge and complex. It's not just one type of broken engine part; it's a whole factory of different parts that can fail in different ways.

This paper tells us that the "rulebook" for diagnosing genetic heart disease has been rewritten. We have more confirmed causes, we understand that children often inherit these issues differently than adults, and we are getting better at telling the difference between a real culprit and a false alarm. It's a giant leap forward for giving families answers and hope.

Technical Summary

1. Problem Statement

Dilated Cardiomyopathy (DCM) is the most common cardiomyopathy, contributing significantly to heart failure with reduced ejection fraction. While the genetic architecture of DCM was partially mapped in a 2019–2020 Clinical Genome Resource (ClinGen) evaluation, five years of rapid scientific advancement have generated a substantial volume of new evidence.

• The Gap: The initial list of 267 candidate genes has expanded to 406. There is an urgent need to reassess previously curated genes and evaluate newly reported gene-disease relationships to distinguish true monogenic causes from genes with limited or disputed evidence.
• The Challenge: DCM exhibits genetic heterogeneity, with contributions from diverse biological ontologies (e.g., sarcomere, cytoskeleton, ion channels) and varying modes of inheritance (Autosomal Dominant [AD] vs. Autosomal Recessive [AR]). Distinguishing between high-confidence causal genes and those with insufficient evidence is critical for clinical genetic testing and variant interpretation.

2. Methodology

The ClinGen DCM Gene Curation Expert Panel (GCEP) reconvened in 2024–2025 to perform a systematic, evidence-based reassessment using the ClinGen semi-quantitative clinical validity classification framework.

• Scope: The panel evaluated 68 genes in total: 51 re-appraised from the previous assessment and 17 newly assessed. This resulted in 72 unique gene-disease-mode of inheritance (MOI) curations.
• Data Sources: A structured literature search was conducted as of January 1, 2024, identifying 406 candidate genes. The panel filtered these for evidence supporting a monogenic, non-syndromic DCM relationship.
• Scoring Framework:
  • Genetic Evidence: Points were assigned for variant data, segregation analysis, and case-control studies. Specific adjustments were made for DCM, such as reducing points for homozygous variants in consanguineous families to avoid over-scoring due to excess homozygosity.
  • Experimental Evidence: Points were awarded for expression data, functional assays, model systems, and rescue experiments.
  • Maximum Score: 18 points (12 genetic + 6 experimental).
• Classification Categories:
  • High Evidence: Definitive (Strong score + >2 independent reports over 3 years), Strong, and Moderate.
  • Low Evidence: Limited, No Known Disease Relationship (NKDR), Disputed, and Refuted.
• MOI Specificity: The panel explicitly separated AD and AR curations where evidence suggested distinct mechanisms (e.g., JPH2, TNNI3), rather than using a "semi-dominant" framework.

3. Key Contributions

• Expanded Genetic Landscape: The assessment identified 35 high-evidence curations (16 Definitive, 10 Strong, 9 Moderate), an increase of 16 from the 2019–2020 assessment.
• Revelation of Recessive Architecture: A major finding is the significant expansion of Autosomal Recessive (AR) DCM causes. Of the 16 new high-evidence curations, 11 (69%) are AR, primarily observed in pediatric DCM and consanguineous families.
• Ontological Diversity: High-evidence genes now span 18 gene ontologies (up from 10), including new groups such as actin-binding, transcription factors, lysosomal function, ribosomal assembly, and mitochondrial energy production.
• Refinement of MOI Mechanisms: The study demonstrated that separating AD and AR curations can drastically alter clinical validity. For example, JPH2 was previously "Moderate" (semi-dominant) but is now "Strong" for AR and "Limited" for AD, clarifying that heterozygous variants may not be pathogenic for DCM.

4. Key Results

• High Evidence Genes (35 Curations):
  • Newly Classified: 9 genes were newly classified as high evidence: BAG5, FLII, LMOD2, MYLK3, MYZAP, NRAP, PPA2, PPP1R13L, and RPL3L.
  • Upgrades: Four previously "Limited" genes were upgraded to high evidence: PLEKHM2 and TNNI3K (to Moderate); PRDM16 and TBX20 (to Strong).
  • Dual MOI: Four genes were curated for both AD and AR: JPH2 (AD-Limited, AR-Strong), LDB3 (AD-Limited, AR-Strong), MYBPC3 (AD-Limited, AR-Limited), and TNNI3 (AD-Strong, AR-Strong).
• Limited Evidence (29 Curations):
  • This category remains the largest, containing 24 AD and 5 AR curations.
  • MYBPC3: Despite accumulating a quantitative score within the "Moderate" range for AD, the panel downgraded MYBPC3 to "Limited" for DCM. The consensus was that the evidence (mostly singleton missense variants without segregation) was insufficient to support a monogenic cause, though it may act as a risk factor.
  • NKDR/Disputed: Four genes were classified as NKDR (LRRC10, NPPA, RTKN2, VEZF1), and four remained Disputed (MYL3, PDLIM3, PKP2, PSEN1).
• Clinical Implications:
  • The updated list of 35 high-evidence curations is recommended as the standard for clinical genetic testing panels for DCM.
  • Variants in "Limited" or "NKDR" genes should generally be classified as Variants of Uncertain Significance (VUS) in clinical practice, whereas variants in "High Evidence" genes can be interpreted as Pathogenic/Likely Pathogenic if they meet ACMG/AMP criteria.

5. Significance

• Clinical Utility: This update provides a rigorous, evidence-based foundation for the interpretation of genetic test results in DCM patients and families. It prevents the misclassification of variants in genes with insufficient evidence as pathogenic, reducing false positives in clinical diagnostics.
• Pediatric Focus: The identification of numerous AR genes highlights the importance of genetic testing for pediatric DCM, particularly in consanguineous populations, where recessive mechanisms are more prevalent.
• Dynamic Framework: The paper underscores that the genetic architecture of DCM is rapidly evolving. The ClinGen process is designed to be iterative, requiring continuous reassessment as new data emerges.
• Complexity of Inheritance: By separating AD and AR mechanisms, the study clarifies that some genes (like JPH2 and TNNI3) have distinct pathogenic mechanisms depending on zygosity, which is crucial for accurate genetic counseling and risk stratification.

In conclusion, this assessment significantly expands the known genetic causes of DCM, shifting the paradigm to include a broader spectrum of recessive genes and diverse biological pathways, thereby refining the standards for clinical genetic testing and care.